NCT06915792 PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy
| NCT ID | NCT06915792 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, Los Angeles |
| Condition | Postpartum Hypertension (PPHT) |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 110 participants in total. It began in 2025-06-01 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.
Eligibility Criteria
Inclusion criteria: Age ≥18 years Delivery at study institution at ≥28 weeks gestation Postpartum SBP \> 150 and/or DBP \> 100 OR 2 or more SBP \> 140 and/or DBP \> 90 within a 24-hour period Require initiation of an oral antihypertensive medication during postpartum hospital stay or within 7 days of discharge Treating obstetric team amenable to starting either study medication Exclusion criteria: Treated with oral antihypertensive medications prior to delivery Known allergies or contraindications to nifedipine or labetalol History of moderate persistent to severe asthma, chronic obstructive pulmonary disease, heart failure, or greater than first-degree atrioventricular heart block Unable to provide written informed consent in English
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06915792 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 64 Years, studying Postpartum Hypertension (PPHT). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06915792 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06915792 currently recruiting?
Yes, NCT06915792 is actively recruiting participants. Contact the research team at tinaanguyen@mednet.ucla.edu for enrollment information.
Where is the NCT06915792 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06915792 clinical trial?
NCT06915792 is sponsored by University of California, Los Angeles. The trial plans to enroll 110 participants.